Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
cash advance payday loan
Popular Articles

International Collaboration Funds Stem Cell Research
The potential of using stem cells to treat Alzheimer"s disease and other illnesses will be investigated by Victorian and Californian researchers under a US$22 million (US$28.7 million) collaboration, Innovation Minister Gavin Jennings said recently.
generic viagra online
Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, And BRAF Gene Mutations In Reflex Testing Service
Quest Diagnostics Incorporated (NYSE: DGX), the world"s leading cancer diagnostics company, today launched the EGFR Pathway test (KRAS with reflex to NRAS, BRAF), the first laboratory-developed test from a national commercial reference laboratory for comprehensively identifying, in a single reflex test offering, genetic mutations in the KRAS, NRAS and BRAFL genes. The test is designed to aid the identification of the roughly half of all metastatic colorectal cancer (mCRC) patients who, because of certain mutations of the epidermal growth factor receptor (EGFR) pathway, are believed to be unresponsive to anti-EGFR cancer therapies for mCRC. While some commercial laboratory tests for predicting anti-EGFR response analyze certain mutations of the KRAS and BRAF genes, such as codons 12 and 13 of KRAS, the Quest Diagnostics test detects mutations in codons 12, 13 and 61 of both the KRAS and NRAS genes and mutations in exons 11, 12, and 15 of the BRAF gene, in a sequential reflex manner.
News of the day
Scientists Assess Flooding And Damage From 2008 Myanmar Cyclone - A Natural Disaster That Killed 138,000
Tropical cyclone Nargis made landfall in the Asian nation of Myanmar on May 2, 2008, causing the worst natural disaster in the country"s recorded history - with a death toll that may have exceeded 138,000. In the July 2009 issue of the journal Nature Geoscience, researchers report on a field survey done three months after the disaster to document the extent of the flooding and resulting damage.
Cardiovascular

Foresight Biotherapeutics Announces Initiation Of Viral Conjunctivitis Clinical Trial

Foresight Biotherapeutics announced that the first patient has been dosed in a viral conjunctivitis clinical trial. Foresight"s proprietary lead compound, FST-100, will be tested in a placebo-controlled, masked, and randomized multicenter clinical study throughout the United States. The primary endpoint of the study is the resolution of clinical signs and symptoms of acute conjunctivitis. Secondary endpoints include a reduction in quantitative PCR (qPCR) viral titers, eradication of infectious virus determined by cell culture immunofluorescence assay (CC-IFA), and safety. The company anticipates enrolling up to 100 patients. This controlled clinical trial follows a successful pilot trial in which the safety and efficacy of FST-100 were demonstrated. In addition, the company recently completed and announced a successful preclinical study in a rabbit model of adenoviral conjunctivitis. Viral conjunctivitis or "pink eye" is the most common eye infection in the developed world. The highly contagious infection is a frequent cause of epidemics in the workplace, schools, medical centers and long term care facilities. Treatment is mostly supportive as there is currently no drug approved by the FDA for viral conjunctivitis. FST-100 is a novel formulation of dexamethasone that includes povidone-iodine. This novel formulation may be able to relieve the discomfort and shorten the course of the illness. Foresight Biotherapeutics looks forward to working with the investigators in conducting this clinical trial and advancing the development of the program. Foresight Biotherapeutics, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009